Loading...
Docoh

ContraFect (CFRX)

ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. The Company intends to address life threatening infections using its therapeutic product candidates from its platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. The Comapny believes that the properties of its lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. It has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with its lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.

CFRX stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 22
24 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 9.55M 9.55M 9.55M 9.55M 9.55M 9.55M
Cash burn (monthly) 29.33K 988.08K 6.68M 5.15M 4.86M 3.83M
Cash used (since last report) 82.96K 2.79M 18.88M 14.56M 13.75M 10.84M
Cash remaining 9.47M 6.75M -9.33M -5.01M -4.2M -1.29M
Runway (months of cash) 322.7 6.8 -1.4 -1.0 -0.9 -0.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 May 22 Aklog Lishan Options Common Stock Grant Acquire A No No 3.35 42,000 140.7K 42,000
17 May 22 Barer Sol J Options Common Stock Grant Acquire A No No 3.35 42,000 140.7K 42,000
17 May 22 Gilman Steven C Options Common Stock Grant Acquire A No No 3.35 42,000 140.7K 42,000
17 May 22 Low David N. Options Common Stock Grant Acquire A No No 3.35 42,000 140.7K 42,000
17 May 22 Otto Michael J. Options Common Stock Grant Acquire A No No 3.35 42,000 140.7K 42,000
13F holders Current Prev Q Change
Total holders 225 245 -8.2%
Opened positions 36 43 -16.3%
Closed positions 56 54 +3.7%
Increased positions 86 91 -5.5%
Reduced positions 60 69 -13.0%
13F shares Current Prev Q Change
Total value 1.15B 2.15B -46.5%
Total shares 246.13M 243.74M +1.0%
Total puts 204.5K 273.1K -25.1%
Total calls 1.2M 1.54M -22.2%
Total put/call ratio 0.2 0.2 -3.8%
Largest owners Shares Value Change
ARK Investment Management 28.05M $157.9M +2.9%
Jackson Square Partners 22.76M $100.61M +1.0%
Vanguard 21.24M $93.89M +6.5%
BLK Blackrock 18.38M $81.25M +10.7%
CMTDF Sumitomo Mitsui Trust 14.35M $63.41M +2.3%
Nikko Asset Management Americas 14.35M $60.97M +2.3%
Madrone Capital Partners 13.42M $122.89M 0.0%
Capital International Investors 11.58M $51.16M -9.4%
TROW T. Rowe Price 10.28M $45.46M +68.5%
GS Goldman Sachs 8.44M $37.3M +190.5%
Largest transactions Shares Bought/sold Change
Casdin Capital 0 -7.99M EXIT
GS Goldman Sachs 8.44M +5.53M +190.5%
TROW T. Rowe Price 10.28M +4.18M +68.5%
Blue Water Life Science Advisors 0 -2.66M EXIT
Two Sigma Advisers 3.58M +2.49M +229.0%
Millennium Management 67.97K -2.37M -97.2%
Citadel Advisors 315.53K -1.93M -86.0%
12 West Capital Management 1.93M +1.93M NEW
SB Management 0 -1.89M EXIT
BLK Blackrock 18.38M +1.77M +10.7%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Good
New words: approximatel, arenot, attrition, bid, burn, Cara, Cassino, Chief, Closure, consecutive, culture, deteriorate, downturn, drawn, DSMB, embrace, IND, inefficiency, morale, motivating, ofthe, power, recession, regain, resignation, saving, sequester, skilled, threshold, turn, unemployment, Unstable, Vice
Removed: America, balanced, blinded, circulate, Combating, concept, concurrence, database, directed, discontinued, dosed, DPA, emergent, expanded, expedite, expedited, Fast, invocation, IV, lot, MSSA, PK, postpone, prioritize, procure, proof, release, responder, responding, simulated, simulation, streamlined, subset, Sustainable, territorial, track, treated, Tribal, undertaken, unmet

Patents

Utility
Therapeutic Protein Formulations Comprising Antibodies and Uses Thereof
1 Sep 22
The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-influenza antibodies or antigen-binding fragments thereof in an amount ranging from 30 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization.
Utility
Lysin polypeptides active against Gram-negative bacteria
16 Aug 22
The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa.
Utility
Method of Treating and Preventing Bone and Joint Infections
23 Jun 22
The present disclosure is directed to a method of treating or preventing a bone or joint infection, which method comprises: administering a therapeutically effective amount of a PlySs2 lysin comprising the amino acid sequence of SEQ ID NO: 1 or a variant thereof having at least 80% identity to SEQ ID NO: 1, wherein the variant comprises bacteriocidal and/or bacteriostatic activity against the Gram-positive bacteria, to a subject in need thereof, optionally co-administered with one or more antibiotics, wherein the bone or joint infection comprises a Gram-positive bacteria, such as Staphylococcus epidermidis or Staphylococcus aureus.
Utility
Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
14 Jun 22
The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present.
Utility
Method of Treating Infective Endocarditis
26 May 22
The present disclosure is directed to a method of treating or preventing infective endocarditis due to Gram-positive bacteria, such as S. aureus, which method includes administering a therapeutically effective amount of a combination of one or more antibiotics, optionally at a sub-Minimum Inhibitory Concentration (MIC) level, and a PlySs2 lysin, such as a single dose of PlySs2 lysin at a sub-MIC level, wherein the one or more antibiotics and the PlySs2 lysin are administered simultaneously or sequentially to a subject in need thereof in any order.